November 14th, 2010
New LVAD Shows Promise as Bridge-to-Transplant
Larry Husten, PHD
ADVANCE (Evaluation of the HeartWare HVAD Left Ventricular Assist Device System for the Treatment of Advanced Heart Failure) evaluated the clinical efficacy of a novel small centrifugal flow pump as a bridge-to-transplant. In the trial, 140 patients who received the device were compared to a contemporaneous control group of 499 similar patients who had received a commercially available LVAD as a bridge-to-transplant. Results of ADVANCE were presented on Sunday at the AHA meeting in Chicago.
At 180 days, 92% of HVAD patients were alive, had received a transplant, or had recovered and no longer needed the device, compared to 90% of controls. This result met the predefined test for noninferiority (P<0.001). The 1-year survival rate was 91% in the HVAD group compared to 86% in the controls.
Compared to baseline, HVAD-treated patients were able to walk farther (113 meters) and had significant improvements in several quality-of-life measures. The investigators reported that the HVAD had a favorable adverse event profile when used as a bridge-to-transplant and that “large quality of life and functional capacity improvements are similar to those obtained with cardiac transplantation.”
One Response to “New LVAD Shows Promise as Bridge-to-Transplant”
NEJM Journal Watch — Recent Cardiology Articles- Transcatheter Valve Replacement for Severe Tricuspid Regurgitation
- Time in Blood Pressure Target Range and Outcomes in Hypertension: Real-World Data
- When to Start Anticoagulation After Ischemic Stroke in Patients with Atrial Fibrillation
- Aortic-Valve Replacement vs. Clinical Surveillance for Asymptomatic Severe Aortic Stenosis
- Secondary Hypertension in Young Adults
It would be interesting to learn about the immunogenicity profile of this VAD and the anticoagulation requirements.
Smaller VADs seem to be a great advantage to the patients.
Competing interests pertaining specifically to this post, comment, or both:
none